

June 21, 2019

To  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

To  
The National Stock Exchange of India Limited  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 001

**Scrip Code: 524558**

**Scrip Code: NEULANLAB  
Series: EQ**

Dear Sir(s),

We wish to inform you that the United States Food and Drug Administration (US FDA) inspected our Unit 1 manufacturing facility at Bonthapally, Hyderabad from 17th to 21st of June 2019.

The inspection has been completed with five observations given under form 483. The Company has already initiated corrective and preventive actions for the observations and is confident of satisfying the FDA within the stipulated time.

This is a regular surveillance audit by USFDA, and no data integrity issues were observed during the inspection.

This is for your information and records.

Yours faithfully,  
For Neuland Laboratories Limited



**Sarada Bhamidipati  
Company Secretary**